Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Febuxostat (Primary) ; Verinurad (Primary)
- Indications Hyperuricaemia; Proteinuria; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 08 Mar 2018 Planned End Date changed from 10 Aug 2018 to 24 Aug 2018.
- 08 Mar 2018 Planned primary completion date changed from 27 Apr 2018 to 30 Apr 2018.
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.